Study Summary
This is a single center, single arm, open-lable phase 1 study to determine the safety and efficacy of CD19-CAR-T cells in patients with relapsed or refractory acute B-cell lymphoblastic leukemia (R/R B-ALL).
Interested in this trial?
Submit an InquiryInterventions
CD19 CAR-T cellsBIOLOGICAL
T cells purified from the PBMC of subjects, transduced with 4-1BB/CD3-ΞΆ lentiviral vector, expanded in vitro for future administration.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Hebei Yanda Ludaopei Hospital | Langfang | Hebei | China |